Mycoplasma Testing: PCR and Traditional Methods for Biotechnology Quality Control
What Is Mycoplasma Testing?
Mycoplasma contamination is one of the most serious and insidious threats to cell culture-based biotechnology production. Mycoplasmas are the smallest self-replicating organisms — wall-less bacteria capable of passing through standard 0.2 µm sterilizing filters — and their presence in cell culture systems causes silent, progressive damage: altered cell metabolism, chromosomal changes, suppressed immune responses, and compromised product quality. Because mycoplasma contamination often produces no visible turbidity, it can go undetected for extended periods, putting entire production campaigns at risk.
Mycoplasma testing is therefore a mandatory quality control requirement for cell culture-based biologics, vaccines, and advanced therapy medicinal products (ATMPs) under USP <63>, EP 2.6.7, and FDA/ICH guidelines.
Why Mycoplasma Testing Is Critical
The consequences of releasing mycoplasma-contaminated biological products are severe — affecting product efficacy, patient safety, and regulatory standing. Key risks include:
- Cell line integrity: Mycoplasma infection alters cellular gene expression, metabolism, and growth kinetics, compromising the consistency and reproducibility of biological production
- Product quality: Contamination affects glycosylation patterns, protein folding, and potency of recombinant proteins and monoclonal antibodies
- Regulatory compliance: Regulatory agencies mandate mycoplasma testing at defined points in the manufacturing cycle — including Master Cell Bank (MCB), Working Cell Bank (WCB), and end-of-production cells
Traditional Methods: Agar/Broth and Indicator Cell Culture
Agar and Broth Medium Procedure (USP <63> Method 1)
The classical microbiological method cultures samples on selective agar plates and in liquid broth under both aerobic and anaerobic conditions over an incubation period of 28 days. Multiple mycoplasma species are targeted, including Acholeplasma laidlawii, Mycoplasma hyorhinis, M. orale, and M. synoviae. The extended incubation reflects the slow growth characteristics of mycoplasma and the need for enrichment to detect low-level contamination.
Advantages: Comprehensive coverage; regulatorily accepted; well-established; cost-effective for routine screening
Limitations: 28-day turnaround limits its utility for real-time manufacturing decisions; some fastidious strains may not grow on standard media
Indicator Cell Culture (Hoechst DNA Stain) Procedure (USP <63> Method 2)
A co-culture method in which the test sample is incubated with an indicator cell line (typically Vero cells). After incubation, the indicator cells are stained with Hoechst 33258 (a DNA fluorochrome) and examined under fluorescence microscopy. Mycoplasma appear as extranuclear fluorescent particles associated with cell membranes.
Advantages: Detects non-cultivable and fastidious mycoplasma species that may not grow in agar/broth media
Limitations: Subjective interpretation; requires skilled microscopists; 14–28 days incubation
PCR-Based Mycoplasma Testing
Polymerase Chain Reaction (PCR) — The Modern Standard
PCR has become the most powerful and widely adopted mycoplasma testing tool in modern biologics manufacturing. Using primers targeting conserved regions of the Mycoplasma 16S rRNA gene, a single PCR assay can detect up to 40 Mycoplasma species simultaneously, with sensitivity to detect as few as 1–10 Mycoplasma organisms per mL of sample.
PCR formats in mycoplasma testing:
Format | Advantage |
Conventional PCR | Established, low-cost gel-based detection |
Real-time quantitative PCR (qPCR) | Faster, quantitative, closed-tube format reduces contamination risk |
Digital PCR (dPCR) | Absolute quantification; highest sensitivity for low-copy detection |
Regulatory Acceptance of PCR
The European Pharmacopoeia 2.6.7 and USP <63> Appendix provide acceptance criteria for PCR-based mycoplasma testing as an alternative to the compendial culture method, subject to method validation including specificity, sensitivity, limit of detection (LOD), and inhibition testing. EMA has issued guidance that accepts validated PCR methods for in-process lot-release testing.
Testing Strategy: When to Apply Each Method
Testing Stage | Recommended Method |
Master Cell Bank (MCB) characterization | Traditional culture + PCR (both required) |
Working Cell Bank (WCB) qualification | Traditional culture + PCR |
In-process and bioreactor monitoring | qPCR (rapid results support real-time decisions) |
Lot release testing | Validated qPCR or traditional culture |
Raw material screening | qPCR |
Industries Served
Mycoplasma testing is critical across the biotechnology and life sciences sectors — including monoclonal antibody manufacturing, vaccine production, cell and gene therapy (CAR-T, AAV vectors), recombinant protein biologics, diagnostic reagent production, and medical device biocompatibility testing using cell-based assays.
Conclusion
Mycoplasma testing is a non-negotiable safeguard in cell culture-based production. Traditional culture methods provide the compendial gold standard recognized by all regulatory agencies, while PCR delivers the speed, sensitivity, and breadth of detection that modern manufacturing timelines demand. A robust mycoplasma control strategy integrates both approaches — applying the right method at the right production stage to deliver maximum protection without unnecessary delay.
Why Choose Infinita Lab for Mycoplasma Testing Services?
Infinita Lab is a trusted USA-based testing laboratory offering mycoplasma testing services — both traditional culture (USP <63>) and validated PCR methods — through an extensive network of accredited facilities nationwide. Infinita Lab is built to serve the full spectrum of modern testing needs across industries, materials, and methodologies. Our advanced equipment and expert professionals deliver highly accurate and prompt test results, helping businesses achieve quality compliance and product reliability.
Looking for a trusted partner to achieve your research goals? Schedule a meeting with us, send us a request, or call us at (888) 878-3090 to learn more about our services and how we can support you. Request a Quote
Frequently Asked Questions (FAQs)
What is the difference between PCR and traditional culture methods for mycoplasma testing? Traditional culture (agar/broth) requires 28 days incubation but provides compendial regulatory acceptance. PCR detects up to 40 species in hours with higher sensitivity. Regulatory guidelines accept validated PCR as an alternative for in-process and lot release testing.
Which mycoplasma species are tested under USP <63>? USP <63> targets species most likely to contaminate cell cultures, including Acholeplasma laidlawii, M. hyorhinis, M. orale, M. synoviae, M. arginini, and a D-glucose-fermenting species. PCR assays typically cover 20–40 additional species using conserved 16S rRNA gene primers.
When is mycoplasma testing required during biologics manufacturing? Testing is mandated at Master Cell Bank establishment, Working Cell Bank qualification, end-of-production cells, and final lot release. In-process monitoring using qPCR is increasingly adopted to enable real-time manufacturing decisions and early contamination detection.
Can mycoplasma contamination be eliminated once detected? Once established in a culture system, mycoplasma contamination is extremely difficult to eradicate. Antibiotic treatment (BM-Cyclin, Plasmocin) may reduce levels but rarely eliminates contamination. Contaminated cell lines are typically discarded and replaced from cryopreserved, mycoplasma-negative stocks.
How is PCR inhibition addressed in mycoplasma testing method validation? Inhibition testing uses a spiked positive control (known mycoplasma added to the test sample matrix) run in parallel with each PCR batch. If the spiked control is detected, the sample matrix is not inhibiting the PCR reaction. Inhibited samples require matrix dilution, purification, or alternative DNA extraction to ensure reliable results.
